

## **InDex Pharmaceuticals Files Five More Patents**

InDex Pharmaceuticals has filed five more patents that will further strengthen its extensive portfolio of proprietary intellectual assets.

"We have complemented our IP assets with some important patents that will add protection to our potential treatments of different diseases related to the immune system", commented Svante Rasmuson, CEO of InDex Pharmaceuticals. "These five patents are all connected to our collection of proprietary DIMS substances (DNA-based Immunomodulatory Sequences) that we believe will be the base of our future immunotherapy franchise."

In total, InDex has filed up to 20 patents that are related either to its pharmaceutical research and development activities or its novel technology of diagnostics used for classification of gastrointestinal diseases.

*Details of the new patents:*

### **MS therapy**

This patent application relates to novel compounds and methods of use for the treatment of MS. It relates in particular to methods to treat MS patients with DIMS compounds that are designed to induce high levels of endogenous interferon- $\beta$ .

### **PMN inhibition**

This patent application relates to novel compounds and methods of use for the treatment and thereby reduction of ischemic tissue and/or organ damage. It relates in particular to methods of use of specific DIMS compounds to prevent migration of immune cells to ischemic areas.

### **CD20, CD23 and CD80 expression**

As expansions to previously filed cancer combination therapy patents, these patent applications relate to novel DIMS compounds and methods of use as treatment enhancers of antibody therapies that target specific receptors present on immune cells.